Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis

Hepatology

Volumn 65, Issue 1, 2017, Pages 152-163

  Dahlqvist, Géraldine ^a,b   Gaouar, Farid ^a   Carrat, Fabrice ^c,d   Meurisse, Sofia ^c,d   Chazouillères, Olivier ^a,e   Poupon, Raoul ^a,e   Johanet, Catherine ^c   Corpechot, Christophe ^a,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c HÔPITAL SAINT ANTOINE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; CHILD; CHOLANGITIS; CHRONIC HEPATITIS C; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INFANT; JAUNDICE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIMARY BILIARY CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SEX RATIO; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; VERY ELDERLY; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MITOCHONDRION; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHOLANGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85001560466     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28859     Document Type: Article

References (30)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353:1261–1273.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237–267.
3. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50:291–308.
4. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965;1:827–831.
5. Munoz LE, Thomas HC, Scheuer PJ, Doniach D, Sherlock S. Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut 1981;22:136–140.
6. Grimbert S, Johanet C, Bendjaballah F, Homberg JC, Poupon R, Beaugrand M. Antimitochondrial antibodies in patients with chronic hepatitis C. Liver 1996;16:161–165.
7. Zamfir O, Briaud I, Dubel L, Ballot E, Johanet C. Anti-pyruvate dehydrogenase autoantibodies in extrahepatic disorders. J Hepatol 1999;31:964–965.
8. James O, Macklon AF, Watson AJ. Primary biliary cirrhosis—a revised clinical spectrum. Lancet 1981;1:1278–1281.
9. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, James OF. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986;6:1279–1284.
10. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996;348:1399–1402.
11. Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C. Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J Hepatol 1995;23:674–680.
12. Galula G, Johanet C, Chazouilleres O, Poupon R. What is the actual frequency of seronegative primary biliary cirrhosis? [in French] Gastroenterol Clin Biol 1999;23:947A.
13. Mortality rates per sex and age groups since 1962: metropolitan France. Demographic situation in 2013. [In French.] In: Insee; 2015. http://www.insee.fr. Accessed on: November 3, 2016.
14. Lin G, So Y, Johnston G. Analyzing Survival Data with Competing Risks Using SAS® Software. In: SAS Institute Inc., ed. SAS Global Forum. Cary, NC: SAS Institute Inc.; 2012:1–8.
15. Onji M, Furukawa S. Significance of study on prevalence of AMA in healthy subjects. J Gastroenterol 2004;39:306–308.
16. Dahlqvist G, Corpechot C. [Are antimitochondrial antibodies the invariable hallmark of primary biliary cirrhosis?]. [Article in French]. Presse Med 2014;43:1311–1313.
17. Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997;26:830–836.
18. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99–103.
19. Lofgren J, Jarnerot G, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol 1985;20:647–650.
20. Mattalia A, Quaranta S, Leung PS, Bauducci M, Van de Water J, Calvo PL, et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998;27:656–661.
21. Omagari K, Rowley MJ, Whittingham S, Jois JA, Byron SL, Mackay IR. Autoantibodies to M2 mitochondrial autoantigens in normal human sera by immunofluorescence and novel assays. J Gastroenterol Hepatol 1996;11:610–616.
22. Turchany JM, Uibo R, Kivik T, Van de Water J, Prindiville T, Coppel RL, Gershwin ME. A study of antimitochondrial antibodies in a random population in Estonia. Am J Gastroenterol 1997;92:124–126.
23. Shibata M, Onozuka Y, Morizane T, Koizumi H, Kawaguchi N, Miyakawa H, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol 2004;39:255–259.
24. Liu HY, Wang LX, Liu YF. [Frequencies of autoantibodies specific for primary biliary cirrhosis in a general adult population group]. [Article in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2008;16:922–925.
25. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 1999;45:756–760.
26. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007;46:1131–1137.
27. Floreani A, Franceschet I, Cazzagon N, Spinazze A, Buja A, Furlan P, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 2015;48:192–197.
28. Prince MI, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of paients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044–1051.
29. Jones DE, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, Newton JL. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol Gastrointest Liver Physiol 2010;298:G764–G773.
30. McDonald C, Newton J, Lai HM, Baker SN, Jones DE. Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms. J Hepatol 2010;53:1095–1100.